[go: up one dir, main page]

WO1991001757A1 - Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent - Google Patents

Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent Download PDF

Info

Publication number
WO1991001757A1
WO1991001757A1 PCT/CA1990/000251 CA9000251W WO9101757A1 WO 1991001757 A1 WO1991001757 A1 WO 1991001757A1 CA 9000251 W CA9000251 W CA 9000251W WO 9101757 A1 WO9101757 A1 WO 9101757A1
Authority
WO
WIPO (PCT)
Prior art keywords
daunorubicin
glutaraldehyde
antibody
conjugate
compounds according
Prior art date
Application number
PCT/CA1990/000251
Other languages
French (fr)
Inventor
Michel Page
Denis Thibeault
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Publication of WO1991001757A1 publication Critical patent/WO1991001757A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin

Definitions

  • Chemotherapeutic agents currently used for antitumour therapy are selected for their toxicity towards rapidly proliferating cells. Most of them cause undesirable systemic effects such as cardiac or renal toxicity, marrow aplasia, alopecia, nausea and vomiting. During the last few years, many authors have tried to eliminate these side effects by increasing the availability of the drug to the tumour site. Enzymes, radioisotopes, DNA, toxins, various macromolecules, and antibodies against fibrin or against tumour-specific surface antigens were bound to drugs in an attempt to increase the selectivity of the chemotherapeutic agents, or to decrease their toxic effects on normal cells (Rubens R.D., Lancet, 1, 1974, pp.498-499; Gregoriadis G. et al., Res. Commun.Chem. Pathol. Pharm., 10, 1977, pp.351-362).
  • Dactinomycin, doxorubicin and daunorubicin are all given rapidly intravenously and all cause tissue necrosis if extravasation
  • SUBSTITUTE SHEET occurs.
  • doxorubicin and daunorubicin are given rapidly intravenously, there is rapid dispersement throughout tissues and plasma.
  • the ⁇ tl/2 is 30 min, with detectable plasma levels of doxorubicin up to 15 h.
  • Both doxorubicin and daunorubicin are extensively metabolized by the liver, yielding active and inactive metabolites.
  • Dactinomycin, doxorubicin and daunorubicin have limited antitumor activity.
  • Dactinomycin is effective in testicular carcinoma and sarcomas.
  • Daunorubicin is effective in treating acute leukemia.
  • doxorubicin is one of the most active antineoplastics ever identified. In fact it is used to treat acute leukemia, Hodgkin's disease and non-Hodgkin's lymphomas, small cell and non-small cell lung cancer, cancers? of the breast, ovaries, stomach, thyroid, and bladder, osteogenic and soft tissue sarcomas, and malignant melanoma.
  • the side effects include nausea, vomiting, alopecia, myelosuppression, and dose-dependent cardiotoxicity (>550 mg/m 2 ).
  • This method is not readily reproducible and give an unstable conjugate product.
  • this autopolymerized antitumor agent has the disadvantage of being insoluble in water and thus looses its specific activity against tumor cells.
  • This insoluble product can not be used intravenously for a systemic treatment since it is taken up by phagocytic cells such as monocytes, macrophage or cells. This product is not very stable and do not have a very long shelf life.
  • antitumor agents which overcome the drawback of the prior art.
  • the already reported techniques for coupling anthracycline d ⁇ ugs to antibody either cause polymerization or yield a product which is considerably less active than the free drug.
  • Using the method of the present invention a wide variety of monoclonal antibodies specific for various tumors are conjugated to other carriers that could be used for drug targeting.
  • - M is selected from the following group consisting of an hydrogen atom , a peptide residue and a protein residue linked to the carbon atom via the amino residue of £-lysine present therein, and
  • - R is an antitumor agent residue such as daunorubicin, doxorubicin, or epirubicin.
  • M When M is a protein, it can be an antibody which is used to target the antitumor agent to the malignant cells and thereby improving the conditions o •_f• such anti-cancer treatments.
  • the compounds of the present invention are easily produced and are devoid of significant polymerization since they are substantially pure.
  • the compounds of the present invention have the ability to
  • B TITUTE SHEET provide the full pharmacological activity of the antitumor agent without the disadvantage normally associated with said antitumor agent.
  • the improved coupling procedure of the present invention involved in the production of these compounds of formula I is readily reproducible and the resulting compounds are substiantially stable at 25 0 C.
  • the products of the present invention are prepared as follows:
  • An antitumor agent R is first reacted with an excess of glutaraldehyde, which gives an intermediate R-glutaraldehyde of formula (I), wherein M is an hydrogen atom.
  • This intermediate reaction product has a terminal aldehyde group.
  • Results- obtained with activated daunorubicin using this new procedure show that the pharmacological activity of the drug could be saved while limiting the undesirable polymerization of the antibody normally encountered with bivalent coupling agents.
  • This procedure is easy and reproducible and reagents are readily available commercially.
  • the activation of the drug can be accomplished in less than 2 hours and the activated drug remains active for a week at room temperature.
  • the activated drug can retain its activity for many months if stored in liquid nitrogen.
  • the cell lines were only used as targets to show that the conjugate can be directed to the desired sites.
  • cell lines there may be used : human embryonic intestine cells (CCL-6), human amnion cells (CCL-25), human osteosarcoma cells (CRL-1427), human ovarian carcinoma (CRL-1572), human hepatoma cells (HS-703-T), Mouse melanoma (CRL-6323) and LoVo human adenocarcinoma cells (CCL- 229).
  • CCL-6 human embryonic intestine cells
  • CCL-25 human amnion cells
  • CL-1427 human osteosarcoma cells
  • human ovarian carcinoma CL-1572
  • human hepatoma cells HS-703-T
  • Mouse melanoma CL-6323
  • LoVo human adenocarcinoma cells CL- 229).
  • the LoVo cells produce carcinoembryonic antigen in culture.
  • the human ovarian carcinoma cells produce alphafoetoprotein. All cell lines are routinely cultured in RPMI-1640® medium supplemented with 10% foetal bovine serum and 100 ug per ml of streptomycin and
  • the antibodies and peptides were only used in order to direct the conjugates to the desired cell lines used.
  • the antibodies were obtained through standard monoclonal antibody production procedures using the above-mentioned cell lines.
  • antibodies there may be used anti-carcinoembryonic monoclonal, anti-carcinoembryonic polyclonal ' antibody, anti-alphafetoprotein monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumine monoclonal antibody.
  • a peptide there may be used: human transferin and lys- bombesin.
  • the conjugate solution is adjusted to 2% bovine serum albumin in 0,05 M ammonium acetate buffer.
  • the solution is then freeze dried and gamma radiated wtih 16 000 rads.
  • the dry conjugate is taken up in Dulbecco® phosphate buffer saline and added at various concentrations to culture medium.
  • cytotoxic activity of daunorubicin and antiCEA conjugate on the various cell lines is evaluated by inhibition of colony formation as described in Emond et al., Anthracyclines, 1983, Ed. G. Mathe, Masson Publish N.Y., U.S.A., 105. Briefly, 2,500 cells are added to 1 ml of RPMI 1640® medium supplemented with 10% foetal bovine serum in 24 well plates. Cells are allowed to attach for 24 hours, medium is removed and replaced by various test compounds diluted in growth medium. The tested drugs are incubated with the cells for four days in complete growth medium. Each assay is performed in quadruplicate.
  • the LD 50 lethal dose to kill 50% of the malignant cells
  • Table 1 The LD 50 (lethal dose to kill 50% of the malignant cells) of free and bound antitumor agent for the various cell lines is reported in Table 1 below.
  • the dosage required to inhibit 50% of the malignant cells for the compounds of the present invention is much lower than for the free drug itself.
  • the LD 50 % decrease is found between 14% to 68% depending on the drug or the cell line used. Compounds with such an ability to target antitumor agents without substantially lowering their pharmaceutical activity were long waited for.
  • the method of the present invention for coupling an anti ⁇ tumor agent to an antibody provides molar ratios of anti-tumor to antibody varying from 0.5:1 to 13:1 as desired.
  • the preferred molar ratios for coupling anti-tumor agent to antibody being 5:1 to 7:1.
  • the glutaraldehyde being used is a 25% aqueous solution of glutaraldehyde in a stoichiometric amount.
  • daunorubicin hydrochloride is dissolved in 4 ml of 0.05 M phosphate buffer at pH 7.5 and 60 ul of 25% glutaraldehyde is added (grade II, Sigma Chemicals, St. Louis, USA). The mixture is stirred for 15 minutes at room temperature and 1 ml of distilled water is added. The mixture is extracted twice with 5 ml of dichloromethane; the organic phases are pooled and treated four times with an equal volume of 5% NaHC03 solution containing 15% glycine. The organic phase is dried with anhydrous sodium sulphate, filtered, and the solvent is evaporated under a stream of nitrogen at room temperature. The dried product is taken in a minimum volume of dimethylsulfoxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to antitumor compounds of formula (I) wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of ε-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin or an epirubicin derivative.

Description

TITLE OF THE INVENTION
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent. BACKGROUND OF THE INVENTION
Chemotherapeutic agents currently used for antitumour therapy are selected for their toxicity towards rapidly proliferating cells. Most of them cause undesirable systemic effects such as cardiac or renal toxicity, marrow aplasia, alopecia, nausea and vomiting. During the last few years, many authors have tried to eliminate these side effects by increasing the availability of the drug to the tumour site. Enzymes, radioisotopes, DNA, toxins, various macromolecules, and antibodies against fibrin or against tumour-specific surface antigens were bound to drugs in an attempt to increase the selectivity of the chemotherapeutic agents, or to decrease their toxic effects on normal cells (Rubens R.D., Lancet, 1, 1974, pp.498-499; Gregoriadis G. et al., Res. Commun.Chem. Pathol. Pharm., 10, 1977, pp.351-362).
The targeting of drugs to a tumour by antibodies to surface antigens may have considerable implications by increasing the therapeutic index.
It is recognized that the ideal antineoplastic drug would destroy cancer cells without adverse effects or toxiάties on normal cells, but no such drug exists. However, despite the narrow therapeutic index of many drugs, treatment and even cure are possible in some patients.
Dactinomycin, doxorubicin and daunorubicin are all given rapidly intravenously and all cause tissue necrosis if extravasation
SUBSTITUTE SHEET occurs. When doxorubicin and daunorubicin are given rapidly intravenously, there is rapid dispersement throughout tissues and plasma. The θ tl/2 is 30 min, with detectable plasma levels of doxorubicin up to 15 h. Both doxorubicin and daunorubicin are extensively metabolized by the liver, yielding active and inactive metabolites.
Dactinomycin, doxorubicin and daunorubicin have limited antitumor activity. Dactinomycin is effective in testicular carcinoma and sarcomas. Daunorubicin is effective in treating acute leukemia. In contrast, doxorubicin is one of the most active antineoplastics ever identified. In fact it is used to treat acute leukemia, Hodgkin's disease and non-Hodgkin's lymphomas, small cell and non-small cell lung cancer, cancers? of the breast, ovaries, stomach, thyroid, and bladder, osteogenic and soft tissue sarcomas, and malignant melanoma. The side effects include nausea, vomiting, alopecia, myelosuppression, and dose-dependent cardiotoxicity (>550 mg/m2).
Relyveld, USP 4,625,019, describes an autopolymerized antitumor agent, that is, daunorubicin is brought in contact with a bifunctional crosslinking agent, such as glutaraldehyde. A form of polymeric product is obtained, which is insoluble in aqueous media but which, on being resuspended in an aqueous medium in the absence of glutaraldehyde, gradually releases the antitumor agent in a soluble form. This method mainly consist of mixing together daunorubicin, an antibody and glutaraldehyde, which can combine in three different ways. The conjugates obtained can be any of the followings: 1- 33% Antibody - glutaraldehyde - Daunorubicin
HEET 2- 33% Antibody - glutaraldehyde - Antibody
3- 33% Daunorubicin - glutaraldehyde - Daunorubicin and which only the Antibody - glutaraldehyde - Daunorubicin conjugate is active. Furthermore, these three possible conjugates can be linked together by the excess glutaraldehyde in solution to form an agglomerate, which makes it difficult to isolate the active conjugate. This is the reason why we refer to an autopolymerized antitumor agent in this patent.
This method is not readily reproducible and give an unstable conjugate product. Unfortunately, this autopolymerized antitumor agent has the disadvantage of being insoluble in water and thus looses its specific activity against tumor cells. This insoluble product can not be used intravenously for a systemic treatment since it is taken up by phagocytic cells such as monocytes, macrophage or cells. This product is not very stable and do not have a very long shelf life.
The problems posed by the administration of antitumor agents or cytostatic agents are made particularly difficult by the nature of the illness and very high toxicity of the active products.
It would be highly desirable if the efficiency of the use of antitumor agents could be improved so as to allow their gradual release in the organism, while clearly improving their efficiency and the patient's comfort. It would also be highly desirable, if there could be such an antitumor agent which would be easily produce, substantially pure, which would also not have a tendency to polymerized and hence have a long shelf life. SUMMARY OF THE INVENTION
Surprisingly and in accordance with the present invention, there is provided antitumor agents which overcome the drawback of the prior art. The already reported techniques for coupling anthracycline dϊugs to antibody either cause polymerization or yield a product which is considerably less active than the free drug. Using the method of the present invention, a wide variety of monoclonal antibodies specific for various tumors are conjugated to other carriers that could be used for drug targeting.
In accordance with the present invention, there is provided novel compounds of the formula I:
0 0
R -C- (CH2 )3 - C -M wherein,
- M is selected from the following group consisting of an hydrogen atom , a peptide residue and a protein residue linked to the carbon atom via the amino residue of £-lysine present therein, and
- R is an antitumor agent residue such as daunorubicin, doxorubicin, or epirubicin.
When M is a protein, it can be an antibody which is used to target the antitumor agent to the malignant cells and thereby improving the conditions o •_f• such anti-cancer treatments.
The compounds of the present invention are easily produced and are devoid of significant polymerization since they are substantially pure. The compounds of the present invention have the ability to
B TITUTE SHEET provide the full pharmacological activity of the antitumor agent without the disadvantage normally associated with said antitumor agent. The improved coupling procedure of the present invention involved in the production of these compounds of formula I is readily reproducible and the resulting compounds are substiantially stable at 250C.
Other advantages of the present invention will be readily illustrated by referring to the following description.
IN THE DRAWINGS
Figure 1 shows the Cytotoxicity of Equimolar Concentrations of
Free or Monoclonal AntiCEA Bound Daunorubicin on Human Colon Adenocarάnoma Cells (LoVo).
Figure 2 shows the Cytotoxicity of Equimolar Concentrations of
Free or Monoclonal AntiCEA Bound Daunorubicin on Human MG-3 Osteosarcoma Cells.
Figure 3 shows the Cytotoxicity of Equimolar Concentrations of
Free or Monoclonal AntiCEA Bound Daunorubicin on Human Amnion Cells.
Figure 4 shows the Cytotoxicity of Equimolar Concentrations of Free or Monoclonal AntiCEA Bound Daunorubicin on Human Embryonic Intestine Cells (CCL-6). DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention correspond to the general formula I:
0 0
II , x II -
R -C- (CH2 )3 - C -M wherein R and M are as defined previously.
The products of the present invention are prepared as follows:
An antitumor agent R is first reacted with an excess of glutaraldehyde, which gives an intermediate R-glutaraldehyde of formula (I), wherein M is an hydrogen atom. This intermediate reaction product has a terminal aldehyde group.
The intermediate reaction product is extracted with a solvant such as dichloromethane to yield a purified activated R-glutaraldehyde having a terminal aldehyde group. This activated R-glutaraldehyde product is then dried on Na-sulfate and dissolved in a solvant such as dimethylsulfoxide (DMSO) and then is reacted with an £-lysine containing protein or peptide to yield the final conjugate R- glutaraldehyde-M. This conjugate is finally obtained by a simple gel filtration.
Results- obtained with activated daunorubicin using this new procedure show that the pharmacological activity of the drug could be saved while limiting the undesirable polymerization of the antibody normally encountered with bivalent coupling agents. This procedure is easy and reproducible and reagents are readily available commercially. The activation of the drug can be accomplished in less than 2 hours and the activated drug remains active for a week at room temperature.
It has also been found that the activated drug can retain its activity for many months if stored in liquid nitrogen.
All the improvements of the R-glutaraldehyde-M conjugate of the present invention can be seen from the following reaction schemes. The method of the present invention is readily reproducible and gives a R-glutaraldehyde-M conjugate, which does not have a tendency to polymerize.
COUPLING OF ANTITUMOR AGENT (R) TO PROTEIN (M) OLD METHOD PRESENT METHOD
R M R + Glutaraldehyde
Figure imgf000009_0001
Glutaraldehyde
Figure imgf000009_0002
Separation o R-glutaraldehyde-M R-glutaraldehyde conjugate by gel filtration
Dichloromethane
1 extraction
R-glutaraldehyde-M Purified activated R-glutaraldehyde
Dry on Na-sulfate Dissolve in DMSO
Activated R-glutaraldehyde + Peptide or Protein
Separation by gel filtration
R-glutaraldehyde-M Cell Lines
The cell lines were only used as targets to show that the conjugate can be directed to the desired sites. As cell lines there may be used : human embryonic intestine cells (CCL-6), human amnion cells (CCL-25), human osteosarcoma cells (CRL-1427), human ovarian carcinoma (CRL-1572), human hepatoma cells (HS-703-T), Mouse melanoma (CRL-6323) and LoVo human adenocarcinoma cells (CCL- 229). These cell lines are readily available from the American Type Culture Collection under the numbers shown in brackets, except for the human hepatoma (HS-703-T) which can be obtained from Dr. Williams C. Parks at Michigan State University, East Lansing, Michigan, U.S.A.
The LoVo cells produce carcinoembryonic antigen in culture.
The human ovarian carcinoma cells produce alphafoetoprotein. All cell lines are routinely cultured in RPMI-1640® medium supplemented with 10% foetal bovine serum and 100 ug per ml of streptomycin and
100 ug per ml of r_enicillin.
Antibody and Peptide
*
The antibodies and peptides were only used in order to direct the conjugates to the desired cell lines used. The antibodies were obtained through standard monoclonal antibody production procedures using the above-mentioned cell lines. As antibodies there may be used : anti-carcinoembryonic monoclonal, anti-carcinoembryonic polyclonal ' antibody, anti-alphafetoprotein monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumine monoclonal antibody. As a peptide there may be used: human transferin and lys- bombesin.
'In vitro' Cytotoxicity
In order to evaluate the efficiency of the compounds of formula (I), the following procedure is used and other methods of in vitro cytotoxicity could have been used.
The conjugate solution is adjusted to 2% bovine serum albumin in 0,05 M ammonium acetate buffer. The solution is then freeze dried and gamma radiated wtih 16 000 rads. Before the assay, the dry conjugate is taken up in Dulbecco® phosphate buffer saline and added at various concentrations to culture medium.
The cytotoxic activity of daunorubicin and antiCEA conjugate on the various cell lines is evaluated by inhibition of colony formation as described in Emond et al., Anthracyclines, 1983, Ed. G. Mathe, Masson Publish N.Y., U.S.A., 105. Briefly, 2,500 cells are added to 1 ml of RPMI 1640® medium supplemented with 10% foetal bovine serum in 24 well plates. Cells are allowed to attach for 24 hours, medium is removed and replaced by various test compounds diluted in growth medium. The tested drugs are incubated with the cells for four days in complete growth medium. Each assay is performed in quadruplicate.
After the growth period, medium is decanted, colonies are fixed with formol and stained with crystal violet as reported in Belles- Isles et al., Brit. J. Cancer, 1980, 41, 840. Following the procedures of the present invention, the following compounds have been obtained:
R M daunorubicin - hydrogen doxorubicin - hydrogen epirubicin - hydrogen daunorubicin - antiCEA doxorubicin - antiCEA epirubicin - antiCEA daunorubicin - antiAFP doxorubicin - antiAFP epirubicin - antiAFP daunorubicin - antiCA-125 doxorubicin - antiCA-125 epirubicin - antiCA-125 daunorubicin -lys-bombesin doxorubicin -lys-bombesin epirubicin -lys-bombesin daunorubicin - antiEPA doxorubicin - antiEPA epirubicin - antiEPA
Cytotoxicity of conjugates
. Results obtained by inhibition of colony formation on the cytotoxicity of free or antiCEA bound daunorubicin are shown on Figures 1 to 4 For any cell line used, we find a dose-response relationship is determined. The cytotoxicity of antiCEA conjugate for LoVo cells is 250 ng/ml as compared to 400 ng/ml for the free drug (Figure 1); the cytotoxicity of antiCEA conjugate for human osteosarcoma (CRL-1427) cells is significantly higher than the one of the free drug (Figure 2). The conjugate is more cytotoxic for normal human amnion cells and human embryonic intestine (CCL-6) than the free drug (Figures 3 and 4).
The LD50 (lethal dose to kill 50% of the malignant cells) of free and bound antitumor agent for the various cell lines is reported in Table 1 below.
12
TABLE 1
Figure imgf000014_0001
It can be seen that the dosage required to inhibit 50% of the malignant cells for the compounds of the present invention is much lower than for the free drug itself. The lower the LD50 the better the drug targetting is and hence less sides effects are observed. The LD50 % decrease is found between 14% to 68% depending on the drug or the cell line used. Compounds with such an ability to target antitumor agents without substantially lowering their pharmaceutical activity were long waited for. The method of the present invention for coupling an anti¬ tumor agent to an antibody provides molar ratios of anti-tumor to antibody varying from 0.5:1 to 13:1 as desired. The preferred molar ratios for coupling anti-tumor agent to antibody being 5:1 to 7:1.
The glutaraldehyde being used is a 25% aqueous solution of glutaraldehyde in a stoichiometric amount.
The present invention will be more readily understood by referring to the following Examples which are given to illustrate the invention rather than to limit its scope.
Example I
A- Glutaraldehyde Activated Daunorubicin
One mg of daunorubicin hydrochloride is dissolved in 4 ml of 0.05 M phosphate buffer at pH 7.5 and 60 ul of 25% glutaraldehyde is added (grade II, Sigma Chemicals, St. Louis, USA). The mixture is stirred for 15 minutes at room temperature and 1 ml of distilled water is added. The mixture is extracted twice with 5 ml of dichloromethane; the organic phases are pooled and treated four times with an equal volume of 5% NaHC03 solution containing 15% glycine. The organic phase is dried with anhydrous sodium sulphate, filtered, and the solvent is evaporated under a stream of nitrogen at room temperature. The dried product is taken in a minimum volume of dimethylsulfoxide
(DMSO).
1% The coefficient of extinction is E 495 = 176 in 10% dimethyl- sulfoxide in 0.05 M phosphate buffer at pH 7.2 for the activated derivative.
B-Antibody Purification
Monoclonal antiCEA 341-46-36 antigen is purified from mouse ascitic fluid by precipitation with 50% saturated ammonium sulphate. The antibody precipitate is dissolved in the original volume of phosphate buffer at pH 7.2 and dialyzed for 24 hours at 4°C against Dulbecco® phosphate buffer saline. The antibody concentration is then measured with the Lowry method (Tsukada, Kato, Umemoto, Takeda, Hara and Hirai, H.J. Nat. Cancer Inst., 1984, 73, 721).
C- Conjugation Procedure
The glutaraldehyde activated daunorubicin derivative is dissolved in 100 ul of dimethylsulfoxide and added with stirring to 500 ug of monoclonal antiCEA antibody dissolved in 400 ul of phosphate buffer. The reaction mixture is incubated for 60 minutes at 37°C and the protein conjugate is separated on Sephadex G-25® on a PD-10® column (Pharmacia, Canada), equilibrated with 0.05 M ammonium acetate at pH 6.5 containing 0.3 mM glycine. The conjugate appears in the void volume of the column. The conjugation ratio is determined by spectrophotometry taking an
1% 1%
E 495 = 176 for daunorubicin and E 28o = 4.5 for monoclonal antibody.
There is obtained the Daunorubicin- Glutaraldehyde -AntiCEA monoclonal antibody conjugate. Example II
Proceding as in example I but using antiAFP antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiAFP- daunorubicin conjugate.
Example III
Proceding as in example I but using antiCA-125 antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiCA-125- daunorubicin conjugate.
Example IV
Proceding as in example I but using antiEPA antibody instead of the antiCEA monoclonal antibody in step B, there is obtained antiEPA- daunorubicin conjugate.
Example V
Proceding as in example I but using lys-bombesin antibody instead of the antiCEA monoclonal antibody in step B, there is obtained lys-bombesin- daunorubicin conjugate.
Example VI
Proceding as in example I but using doxorubicin instead of daunorubicin in step B, there is obtained antiCEA-doxorubicin conjugate. Example VII
Proceding as in example π but using doxorubicin instead of daunorubicin in step B, there is obtained antiAFP-doxorubicin conjugate. Example VIII
Proceding as in example HI but using doxorubicin instead of daunorubicin in step B, there is obtained antiCA-125- doxorubicin conjugate.
Example IX
Proceding as in example IV but using doxorubicin instead of daunorubicin in step B, there is obtained antiEPA-doxorubicin conjugate.
Example X
Proceding as in example V but using doxorubicin instead of daunorubicin in step B, there is obtained lys-bombesin-doxorubicin conjugate.
Example XI
Proceding as in example I but using epirubicin instead of daunorubicin in step B, there is obtained antiCEA-epirubicin conjugate. Example XII
Proceding as in example II but using epirubicin instead of daunorubicin in step B, there is obtained antiAFP-epirubicin conjugate. Example XIII
Proceding as in example III but using epirubicin instead of daunorubicin in step B, there is obtained antiCA-125-epirubicin conjugate. Example XIV
Proceding as in example IV but using epirubicin instead of daunorubicin in step B, there is obtained antiEPA-epirubicin conjugate.
Example XV
Proceding as in example V but using epirubicin instead of daunorubicin in step B, there is obtained lys-bombesin-epirubicin conjugate.

Claims

I CLAIM :
1. Compounds of the formula I :
0 0
R -C- (CH2 )- - C - M wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of 8-lysine present therein, and wherein R represents the anti-tumor agent residue.
2. Compounds according to Claim 1, wherein M is an hydrogen atom.
3. Compounds according to Claim 1, wherein said antitumor agent is selected from daunorubicin.
4. Compounds according to Claim 1, wherein said antitumor agent is selected from doxorubicin.
5. Compounds according to Claim 1, wherein said antitumor agent is selected from epirubicin.
6. Compounds according to Claim 1, wherein said compound of formula I is antiCEA monoclonal antibody-daunorubicin conjugate.
7. Compounds according to Claim 1, wherein M is a peptide selected from the group consisting of anti-carcinoembryonic monoclonal, anti-carcinoembryonic polyclonal antibody, anti- alphafetoprotein monoclonal, anti-alphafetoprotein polyclonal antibody, anti-embryonic pre-albumine monoclonal antibody, human transferin and lys-bombesin.
8. A method of preparing the compounds of Claim 1, which consists in the steps of:
a- reacting said antitumor agent with glutaraldehyde;
b- purifying the activated product by extraction with dichloromethane; and
c- reacting the drug-glutaraldehyde complex of step a) with a peptide or a protein M.
9. A method for treating cancer which comprises administering to a host a therapeutic dosage of a compound of formula I.
10. The method according to Claim 9, wherein the active ingredient is antiCEA monoclonal antibody-daunorubicin conjugate.
PCT/CA1990/000251 1989-08-10 1990-08-09 Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent WO1991001757A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39192889A 1989-08-10 1989-08-10
US391,928 1989-08-10

Publications (1)

Publication Number Publication Date
WO1991001757A1 true WO1991001757A1 (en) 1991-02-21

Family

ID=23548555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1990/000251 WO1991001757A1 (en) 1989-08-10 1990-08-09 Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent

Country Status (2)

Country Link
CA (1) CA2021942C (en)
WO (1) WO1991001757A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310039B1 (en) 1996-09-11 2001-10-30 Felix Kratz Antineoplastic conjugates of transferrin, albumin and polyethylene glycol

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074279A2 (en) * 1981-09-08 1983-03-16 Suntory Limited Selective anti-tumour agents
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0114685A2 (en) * 1983-01-21 1984-08-01 The Green Cross Corporation Fibronectin complexes
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074279A2 (en) * 1981-09-08 1983-03-16 Suntory Limited Selective anti-tumour agents
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0114685A2 (en) * 1983-01-21 1984-08-01 The Green Cross Corporation Fibronectin complexes
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anticancer Research, Volume 10, No. 2A, March-April 1990, M. PAGE et al.: "Coupling a Preactivated Daunorubicin Derivative to Antibody. A New Approach", pages 353-357 see the whole article *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310039B1 (en) 1996-09-11 2001-10-30 Felix Kratz Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
US6709679B2 (en) 1996-09-11 2004-03-23 Felix Kratz Antineoplastic conjugates of transferin, albumin and polyethylene glycol

Also Published As

Publication number Publication date
CA2021942A1 (en) 1991-02-11
CA2021942C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
US5208323A (en) Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
AU767394B2 (en) Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
KR960015398B1 (en) Anthracycline immunoconjugates having a novel linker and method for their production
US5004606A (en) Non-covalent antibody-anthracycline immunocomplexes
US5783178A (en) Polymer linked biological agents
ES2623017T5 (en) Procedure for the preparation of an injectable drug formulation
US4401592A (en) Pharmaceutical composition having antitumor activity
US5514794A (en) Antibody-drug conjugates
Zunino et al. Anti‐tumor activity of daunorubicin linked to poly‐l‐aspartic acid
CN113941007B (en) Tandem double-drug linked assembly unit and application thereof
AU3593093A (en) Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
Zunino et al. Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers
WO2006092229A1 (en) Protein-binding anthracyclin peptide derivatives and medicaments comprising the same
US4485093A (en) Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
EP0398305B1 (en) Anthracycline conjugates having a novel linker and methods for their production
EP0584034A2 (en) Cytotoxic drug conjugates for treatment of neoplastic diseases
WO1993025225A1 (en) Liposomal formulations for administering to cancer patients
AU622105B2 (en) Immunoglobulin conjugates
Wilchek Affinity therapy and polymer bound drugs
CA2021942C (en) Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
Preobrazhenskaya et al. Second generation drugs-derivatives of natural antitumor anthracycline antibiotics daunorubicin, doxorubicin and carminomycin
NZ533849A (en) Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
RU2009500C1 (en) Method for preparation of cytotoxic conjugation
CN111973608B (en) Use of sialic acid derivative
Thibeault et al. Coupling daunorubicin to monoclonal antialphafoetoprotein with a new activated derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE